C 201

Drug Profile

C 201

Alternative Names: C-201; Neurodur

Latest Information Update: 10 Mar 2011

Price : $50

At a glance

  • Originator CepTor Corporation
  • Class Amino acids; Anti-ischaemics; Antithrombotics; Heart failure therapies
  • Mechanism of Action Calpain inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Multiple sclerosis

Most Recent Events

  • 16 Oct 2006 Clinical data from a media release have been added to the Neurological disorders pharmacodynamics section
  • 01 Mar 2005 Ceptor Corporation is now an independent company
  • 09 Dec 2003 Preclinical trials in Multiple sclerosis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top